Literature DB >> 25594458

PTENtiating autoimmunity through Treg cell deregulation.

John P Ray1, Joe Craft2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25594458      PMCID： PMC4447107          DOI： 10.1038/ni.3082

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  11 in total

1.  PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.

Authors:  Patrick T Walsh; Jodi L Buckler; Jidong Zhang; Andrew E Gelman; Nicole M Dalton; Devon K Taylor; Steven J Bensinger; Wayne W Hancock; Laurence A Turka
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

Review 2.  Regulation of immune responses by mTOR.

Authors:  Jonathan D Powell; Kristen N Pollizzi; Emily B Heikamp; Maureen R Horton
Journal:  Annu Rev Immunol       Date:  2011-11-29       Impact factor: 28.527

3.  IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.

Authors:  Matthew A Burchill; Jianying Yang; Christine Vogtenhuber; Bruce R Blazar; Michael A Farrar
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.

Authors:  Ryan D Michalek; Valerie A Gerriets; Sarah R Jacobs; Andrew N Macintyre; Nancie J MacIver; Emily F Mason; Sarah A Sullivan; Amanda G Nichols; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2011-02-11       Impact factor: 5.422

Review 5.  Regulatory T cells: mechanisms of differentiation and function.

Authors:  Steven Z Josefowicz; Li-Fan Lu; Alexander Y Rudensky
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

6.  Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice.

Authors:  Xiaohe Liu; Jodi L Karnell; Bu Yin; Ruan Zhang; Jidong Zhang; Peiying Li; Yongwon Choi; Jonathan S Maltzman; Warren S Pear; Craig H Bassing; Laurence A Turka
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

7.  Interferon-γ excess leads to pathogenic accumulation of follicular helper T cells and germinal centers.

Authors:  Sau K Lee; Diego G Silva; Jaime L Martin; Alvin Pratama; Xin Hu; Pheh-Ping Chang; Giles Walters; Carola G Vinuesa
Journal:  Immunity       Date:  2012-11-16       Impact factor: 31.745

8.  Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response.

Authors:  Samantha L Bailey-Bucktrout; Marc Martinez-Llordella; Xuyu Zhou; Bryan Anthony; Wendy Rosenthal; Herve Luche; Hans J Fehling; Jeffrey A Bluestone
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

9.  STAT5 is a potent negative regulator of TFH cell differentiation.

Authors:  Robert J Johnston; Youn Soo Choi; Jeffrey A Diamond; Jessica A Yang; Shane Crotty
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

10.  Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells.

Authors:  Kenneth J Scalapino; David I Daikh
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240
View more
  6 in total

Review 1.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

Review 2.  The functions of tumor suppressor PTEN in innate and adaptive immunity.

Authors:  Lang Chen; Deyin Guo
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

Review 3.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

4.  Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome.

Authors:  Zhi-wei Lai; Ivan Marchena-Mendez; Andras Perl
Journal:  Clin Immunol       Date:  2015-04-08       Impact factor: 3.969

5.  The identification of up-regulated ebv-miR-BHRF1-2-5p targeting MALT1 and ebv-miR-BHRF1-3 in the circulation of patients with multiple sclerosis.

Authors:  Y F Wang; D D He; H W Liang; D Yang; H Yue; X M Zhang; R Wang; B Li; H X Yang; Y Liu; Y Chen; Y X Duan; C Y Zhang; X Chen; J Fu
Journal:  Clin Exp Immunol       Date:  2017-03-28       Impact factor: 4.330

Review 6.  The new progress in cancer immunotherapy.

Authors:  Ajmeri Sultana Shimu; Hua-Xing Wei; Qiangsheng Li; Xucai Zheng; Bofeng Li
Journal:  Clin Exp Med       Date:  2022-09-15       Impact factor: 5.057
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.